01-18-2019 10:13 AM CET - Health & Medicine

Antidiabetics Market 2018 – 2024 Global Key Leaders: Novartis AG, Sanofi, Bayer Corporation, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, Pfizer

Press release from: marketstudyreport.com
PR Agency: Antidiabetics Market

Market Study Report LLC recently introduced new title on “2018-2024 Global Antidiabetics Market Report” that provides an in-depth overview of industry and competitive landscape, covering multiple market segments and elaborates market outlook and status to 2024.

Germany antidiabetics industry accounted for largest revenue size of USD 4,461.7 million of Europe antidiabetics industry in 2017. According to WHO, in 2016, it was estimated that 22.7% people in Germany are suffering from obesity which is the major risk factor associated with diabetes. Mortality rate due to diabetes is also increasing at fast pace. Moreover, availability of medicines, technologies and facilities for the disease treatment will stimulate German antidiabetics market growth.

Request a sample of this premium report at: www.marketstudyreport.com/request-a-sample/467744/

Growing incidence coupled with increasing risk of diabetes will augment antidiabetics market growth over the coming years. Excess weight significantly escalates risk of type 2 diabetes mellitus (T2DM). Also, the risk of developing diabetes by 25 years of age increases four times in obese children. Thus, rising incidence of diabetes will result into substantial rise in demand for antidiabetics, thereby impelling antidiabetics business growth. Antidiabetics Market will reach over USD 110 billion by 2024; as per a new research report.

With accelerating growth in number of diabetes cases, prominent players are concentrating their efforts on developing newer and improved antidiabetic drugs. Many leading players including Sanofi, Novo Nordisk and Eli Lilly have a broad pipeline portfolio of antidiabetic drugs that aim to diversify the set of therapeutic alternatives for diabetes patients. Thus, growing R&D activities should positively impact antidiabetics industry growth in forthcoming timeframe.

Insulin product segment is estimated to witness 12.3% CAGR during the forecast period. High revenue share is attributable to widening use of insulin therapy for the treatment of type 2 diabetes. Besides, insulin is available in several forms depending upon its rate of action. In addition, insulin therapy decreases microvascular complications that should boost adoption rate of insulin in the upcoming years.

Request a discount on standard prices of this premium report at: www.marketstudyreport.com/check-for-discount/467744/

Geriatric patient population segment accounted for nearly 42.2% market share in 2017 and is estimated to follow similar trend during the forecast timeline. T2DM is an emerging problem in elderly population. As per American Diabetes Association, about 25% of Americans aged above 60 years of age suffer from diabetes. The risk in treating diabetes through changes in dietary habits is further elevated due to impaired physical functioning. Such factors coupled with rising awareness to educate older population about reducing risk of diabetes will act as high impacting factor for geriatric segment growth.

Oral route of administration segment accounted for 72.6% market share in 2017 and will grow at a significant pace during the forecast timeframe due to effectivity and efficacy of treatment coupled with convenience. A study conducted by International Journal of Pharmaceutical Research indicated that oral antidiabetics are most frequently prescribed hypoglycemics. Above factors will highly contribute to segmental growth in projected period.

India antidiabetics market is estimated to progress at 14.3% CAGR during the forecast timeframe. Growing adoption of binge eating habits as well as accelerating elderly population will considerably contribute to increase in Indian antidiabetics market. Additionally, firms are undertaking organic growth initiatives to expand in Indian market. For instance, Lupin and Boehringer Ingelheim collaborated for co-marketing its oral antidiabetics across India, that should offer lucrative market growth potential in forthcoming years.

Some of the major market players involved in global antidiabetics market are Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Companies are focusing on partnerships and novel product launch to expand their market presence and enhance customer portfolio.

Table of Content:

Chapter 1. Methodology

1.1. Methodology

1.2. Market definitions

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary Paid sources Unpaid sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. Antidiabetics industry 360 degree synopsis, 2013 - 2024 (USD Million)

2.1.1. Business trends

2.1.2. Product trends

2.1.3. Patient population trends

2.1.4. Route of administration trends

2.1.5. Regional trends

Chapter 3. Antidiabetics Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 - 2024

3.3. Industry impact forces

3.3.1. Growth drivers Strong product pipeline of antidiabetics Globally rising prevalence of diabetes Increasing prevalence of lifestyle induced disorders such as obesity

3.3.2. Industry pitfalls and challenges Prohibitive cost of insulin

3.4. Regulatory landscape

3.4.1. U.S.

3.4.2. Europe

3.5. Clinical workflow analysis

3.6. Reimbursement scenario

3.6.1. U.S.

3.6.2. Europe

3.6.3. Australia

3.7. Growth potential analysis

3.7.1. By product

3.7.2. By patient population

3.7.3. By route of administration

3.8. Porter's analysis

3.9. Competitive landscape

3.9.1. Company market share analysis, 2017

3.9.2. Strategy dashboard

3.10. PESTEL analysis

3.11. Pipeline overview, 2018

Chapter 4. Antidiabetics Market, By Product

4.1. Key segment trends

4.2. Insulin

4.2.1. Market size, by region, 2013-2024 (USD Million)

For more information on this report at: www.marketstudyreport.com/reports/antidiabetics-market/?u...

Related Report:

Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Antidiabetics Market 2018, Forecast to 2023

The North American antidiabetics market held the largest market revenue share in 2013. High market penetration of modern insulin products such as long-acting, rapid acting insulin analogs and DPP-4 drugs such as Januvia, Onglyza and Nesina and the presence of high healthcare expenditures, patient awareness levels, sophisticated healthcare infrastructure and reimbursement framework are the major factors contributing to its large share.
Asia Pacific on account of the rapidly improving healthcare expenditure levels, growing prevalence of type I and type II diabetes and increasing patient disposable incomes is expected to grow at the fastest rate during the forecast period.


About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:
Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: www.marketstudyreport.com
Blog: www.marketstudyreport.com/blog/

This release was published on openPR.
News-ID: 1511529 • Views: 213
More releasesMore releases

You can edit or delete your press release here: